UCB cuts 2,000 jobs worldwide
About 550 at Belgium UCB will lose their jobs in the pharmaceutical giant’s restructuring programme.29 August 2008
BELGIUM -- About 550 UCB employees will be axed in the Belgian pharmaceutical giant’s recently-announced restructuring programme.
In the company’s revamp programme known as SHAPE, 2,000 jobs or 17 percent of its global workforce will be let go.
In Belgium, about 130 employees based at UCB headquarters in Brussels and 425 working at the research and production facility in Braine l'Alleud are expected to be retrenched.
UCB hopes that the restructuring will help to re-deploy its resources towards its growth drivers and core assets. Non-core activities will be outsourced. The company also hopes to simplify its organisation.
UCB's chief personnel officer Jean-Christophe Donck told journalists that: "Around 550 jobs will go in Belgium…. (but) about 100 new jobs will be created and around 80 positions will be transferred to Belgium from UCB-sites abroad."
All together just under 400 jobs will be lost in Belgium."
Despite the job cuts, Donck stressed that Belgium remains an important strategic platform for UCB's global expansion.
A global player
UCB was originally a local Belgian company known as Union Chimique Belge (Belgian Chemical Union). The company has since expanded into a multi-national with branches in 40 countries.
UCB has two sites in Belgium at Anderlecht (Greater Brussels) and Braine l'Alleud (Walloon Brabant).
UCB's Anderlecht site is the company's global headquarters, while Braine l'Alleud is UCB's global research, production and support centre.
One of UCB's best known products is the antihistamine Zyrtec.
The company had a worldwide turnover of EUR 3.5 billion in 2007.
[flandersnews.be / Expatica]